Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018732 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
A Phase 2 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT01018732 is a Phase 2 study that has completed, run by Novartis Vaccines. The registered enrollment target is 155 participants.
The verdict
NCT01018732, a Phase 2 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescent subjects who completed study V59P6 in which they received either Novartis Meningococcal (MenACWY) Conjugate Vaccine or Licensed polysaccharide Men ACWY vaccine (Menomune®). The study will also enroll age-matched subjects who have never received any other meningococcal vaccine (naïve subjects) to serve as an additional control group.
Interventions
- BIOLOGICAL Novartis Meningococcal (MenACWY-CRM) vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01018732
The ClinicalTrials.gov registry entry for NCT01018732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novartis Meningococcal (MenACWY-CRM) vaccine is the first listed.
NCT01018732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01018732 about?
NCT01018732 is a clinical study titled "A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY". The primary objective is to evaluate the persistence of bactericidal antibodies in adolescent subjects who completed study V59P6 in which they received either Novartis Meningococcal (MenACWY) Conjugate Vaccine or Licensed polysaccharide Men ACWY vaccine (Menomune®). The study will also enroll age-ma...
What is the current status of trial NCT01018732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2010-01. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01018732?
The interventions under investigation include: Novartis Meningococcal (MenACWY-CRM) vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01018732?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.